Capstone Asset Management Co. Sells 2,575 Shares of Teva Pharmaceutical Industries Limited (TEVA)

Capstone Asset Management Co. cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,044 shares of the company’s stock after selling 2,575 shares during the period. Capstone Asset Management Co.’s holdings in Teva Pharmaceutical Industries Limited were worth $799,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Sii Investments Inc. WI raised its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after buying an additional 25 shares in the last quarter. Salem Investment Counselors Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after buying an additional 32 shares in the last quarter. Cribstone Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Financial Architects Inc raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Institutional investors own 56.04% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 1.17% during midday trading on Friday, reaching $17.30. 9,162,890 shares of the company’s stock traded hands. The stock’s market cap is $17.58 billion. The stock has a 50 day moving average of $27.46 and a 200-day moving average of $30.98. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the business earned $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.

Several analysts recently issued reports on TEVA shares. Citigroup Inc. cut their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, April 25th. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $35.15 target price on the stock. in a research report on Monday, April 24th. Credit Suisse Group reissued a “buy” rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th. Deutsche Bank AG lowered their target price on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 12th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 31st. Three equities research analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $36.73.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.